Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Intelsius Introduces Reusable Courier Transit Case

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
BioCarrier™ - Designed for local courier routes and multiple site sample collections.

Intelsius has introduced the first of its kind range of solutions, BioCarrier™, specifically designed for local courier routes and multiple site sample collections.

“Intelsius is proudly introducing the BioCarrier line to the life science leaders and industry professionals at the largest and most well attended clinical trial conference of the year,” said David Walsh, CEO, Intelsius. “This is a regulatory compliant solution rather than couriers carrying samples or medicines from clinic to clinic or pharmacy to pharmacy in picnic coolers.”

BioCarrier cases are designed to provide regular route, multiple site sample collection and “home visit” temperature-sensitive injectable drug protection.

The rugged polymer outer with the expanded polypropylene (EPP) insulated liner maintains payload integrity at 2-8 degrees Celsius for 12 hours plus or when using dry ice up to 18 hours.

All three sizes are regulatory compliant with pre-printed UN3373 labels for the shipment of Category B biological samples.

“The rigid, durable, regulatory compliant marked outer cases feature a clasp closure allowing the lid to be secured and the cases to be stacked and locked together, making them an Intelsius exclusive,” said Alex Roskoss, Intelsius European head of technical services.

“These cases were ergonomically designed specifically for couriers to enable safe, comfortable, compliant transportation around the corner or across town,” Roskoss added. Its discreet design keeps the contents confidential.

“Keeping people safe while samples or medicines are being transported around town is the primary reason for creating the BioCarrier line of products,” said Walsh.

Intelsius serves a wide range of organizations, including government agencies, leading pharmaceutical, biopharmaceutical and clinical research industries to major laboratories.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!